This elevation in baseline SH3YL1 levels in patients, irrespective of acute treatment response, suggests that SH3YL1 may reflect the underlying chronic pathology associated with MIBC rather than serve as an immediate marker for cisplatin-induced acute kidney injury. The gene discussed is SH3YL1; the disease is kidney injury.